Literature DB >> 25651961

Hepatocellular carcinoma with bile duct tumor thrombus: surgical outcomes and the prognostic impact of concomitant major vascular invasion.

Yosuke Kasai1, Etsuro Hatano, Satoru Seo, Kojiro Taura, Kentaro Yasuchika, Shinji Uemoto.   

Abstract

BACKGROUND: The aim of this study was to clarify the long-term surgical outcomes of hepatocellular carcinoma (HCC) with bile duct tumor thrombus (BDTT) and to identify a therapeutic strategy for this condition.
METHODS: Forty-four patients who underwent hepatectomy for HCC with BDTT or direct invasion involving the first branches of the bile duct or common hepatic duct were enrolled in this study. The overall survival time and time to recurrence were analyzed.
RESULTS: The median survival time and the 5-year survival rate were 23.7 months and 31.0%, respectively. Child-Pugh classification B [hazard ratio (HR) 4.92; 95% confidence interval (CI) 1.97-11.65], major vascular invasion (MVI; HR 2.79; 95% CI 1.14-6.87), and serosal invasion (HR 2.71; 95% CI 1.19-6.02) were independent prognostic factors for overall survival. The median survival times were 12.3 and 72.3 months for the patients with and without MVI, respectively. Among the 41 patients who underwent macroscopic curative resection, the median time to recurrence and the 5-year recurrence rate were 8.6 months and 85.6%, respectively. MVI was the only independent prognostic factor for recurrence (HR 3.31; 95% CI 1.55-7.05). The median times to recurrence were 3.7 and 11.6 months for the patients with and without MVI, respectively.
CONCLUSIONS: Concomitant MVI was a strong prognostic factor in the setting of HCC with BDTT. Extended hepatectomy provided a good prognosis for the patients with BDTT alone without MVI.

Entities:  

Mesh:

Year:  2015        PMID: 25651961     DOI: 10.1007/s00268-015-2985-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

1.  New simple technique for hepatic parenchymal resection using a Cavitron Ultrasonic Surgical Aspirator and bipolar cautery equipped with a channel for water dripping.

Authors:  Y Yamamoto; I Ikai; M Kume; Y Sakai; A Yamauchi; H Shinohara; T Morimoto; Y Shimahara; M Yamamoto; Y Yamaoka
Journal:  World J Surg       Date:  1999-10       Impact factor: 3.352

2.  Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein.

Authors:  Iwao Ikai; Etsuro Hatano; Suguru Hasegawa; Hideaki Fujii; Kojiro Taura; Naoki Uyama; Yasuyuki Shimahara
Journal:  J Am Coll Surg       Date:  2006-01-20       Impact factor: 6.113

3.  Icteric type hepatoma.

Authors:  T Y Lin; K M Chen; Y R Chen; W S Lin; T H Wang; J L Sung
Journal:  Med Chir Dig       Date:  1975

4.  Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion.

Authors:  Naoki Ikenaga; Kazuo Chijiiwa; Kazuhiro Otani; Jiro Ohuchida; Shuichiro Uchiyama; Kazuhiro Kondo
Journal:  J Gastrointest Surg       Date:  2008-11-15       Impact factor: 3.452

5.  Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS).

Authors:  Nuh N Rahbari; O James Garden; Robert Padbury; Mark Brooke-Smith; Michael Crawford; Rene Adam; Moritz Koch; Masatoshi Makuuchi; Ronald P Dematteo; Christopher Christophi; Simon Banting; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yukihiro Yokoyama; Sheung Tat Fan; Yuji Nimura; Joan Figueras; Lorenzo Capussotti; Markus W Büchler; Jürgen Weitz
Journal:  Surgery       Date:  2011-01-14       Impact factor: 3.982

6.  Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi.

Authors:  S Satoh; I Ikai; G Honda; H Okabe; O Takeyama; Y Yamamoto; N Yamamoto; Y Iimuro; Y Shimahara; Y Yamaoka
Journal:  Surgery       Date:  2000-11       Impact factor: 3.982

7.  Hepatocellular carcinoma with biliary tumor thrombi: aggressive operative approach after appropriate preoperative management.

Authors:  M Shiomi; J Kamiya; M Nagino; K Uesaka; T Sano; N Hayakawa; M Kanai; H Yamamoto; Y Nimura
Journal:  Surgery       Date:  2001-06       Impact factor: 3.982

8.  Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old.

Authors:  Kojiro Taura; Iwao Ikai; Etsuro Hatano; Hideaki Fujii; Naoki Uyama; Yasuyuki Shimahara
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

9.  Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: experience of 34 patients.

Authors:  Lun-Xiu Qin; Zeng-Chen Ma; Zhi-Quan Wu; Jia Fan; Xin-Da Zhou; Hui-Chuan Sun; Qing-Hai Ye; Lu Wang; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

10.  The impact of posthepatectomy liver failure on the recurrence of hepatocellular carcinoma.

Authors:  Kohta Iguchi; Etsuro Hatano; Kenya Yamanaka; Shiro Tanaka; Kojiro Taura; Shinji Uemoto
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

View more
  16 in total

1.  Living Donor Liver Transplantation for Hepatocellular Carcinoma with Bile Duct Tumor Thrombi.

Authors:  Ufuk Uylas; Huseyin Kerem Tolan; Volkan Ince; Cuneyt Kayaalp; Sezai Yilmaz
Journal:  J Gastrointest Cancer       Date:  2018-12

Review 2.  Systematic review and meta-analysis of outcomes after liver resection in patients with hepatocellular carcinoma (HCC) with and without bile duct thrombus.

Authors:  Suresh Navadgi; Chi-Chun Chang; Adam Bartlett; John McCall; Sanjay Pandanaboyana
Journal:  HPB (Oxford)       Date:  2016-02-18       Impact factor: 3.647

3.  Bile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinoma.

Authors:  Ye-Rang Jang; Kwang-Woong Lee; Hyeyoung Kim; Jeong-Moo Lee; Nam-Joon Yi; Kyung-Suk Suh
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2015-11-30

4.  Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion.

Authors:  Jihyun An; Kwang Sun Lee; Kang Mo Kim; Do Hyun Park; Sang Soo Lee; Danbi Lee; Ju Hyun Shim; Young-Suk Lim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee
Journal:  Clin Mol Hepatol       Date:  2017-05-16

5.  Extrahepatic bile duct hepatocellular carcinoma due to recurrence of hematogenous metastasis 50 months after hepatectomy.

Authors:  Hiroyuki Kumata; Shigehito Miyagi; Keigo Murakami; Atsushi Fujio; Yasuyuki Hara; Chikashi Nakanishi; Naoki Kawagishi; Hironobu Sasano; Takashi Kamei; Noriaki Ouchi
Journal:  Surg Case Rep       Date:  2017-02-16

6.  Hepatocellular carcinoma with hilar bile duct tumor thrombus versus hilar Cholangiocarcinoma on enhanced computed tomography: a diagnostic challenge.

Authors:  Xiaoqi Zhou; Jifei Wang; Mimi Tang; Mengqi Huang; Ling Xu; Zhenpeng Peng; Zi-Ping Li; Shi-Ting Feng
Journal:  BMC Cancer       Date:  2020-01-22       Impact factor: 4.430

7.  Comparison of different surgical interventions for hepatocellular carcinoma with bile duct tumor thrombus: a systematic review and meta-analysis.

Authors:  Jin-Kai Feng; Zhen-Hua Chen; Yu-Xuan Wu; Kang Wang; Ju-Xian Sun; Zong-Tao Chai; Wei-Xing Guo; Jie Shi; Shu-Qun Cheng
Journal:  Ann Transl Med       Date:  2020-12

Review 8.  Surgical outcomes of hepatocellular carcinoma with biliary tumor thrombus: a systematic review.

Authors:  Wenhui Qiao; Feng Yu; Lupeng Wu; Bin Li; Yanming Zhou
Journal:  BMC Gastroenterol       Date:  2016-01-28       Impact factor: 3.067

9.  Small molecule metabolite biomarkers for hepatocellular carcinoma with bile duct tumor thrombus diagnosis.

Authors:  Weifeng Tan; Jingquan He; Junliang Deng; Xinwei Yang; Longjiu Cui; Rongzheng Ran; Guangwei Du; Xiaoqing Jiang
Journal:  Sci Rep       Date:  2018-02-19       Impact factor: 4.379

10.  Definition of a novel vascular invasion-associated multi-gene signature for predicting survival in patients with hepatocellular carcinoma.

Authors:  Bo Yi; Caixi Tang; Yin Tao; Zhijian Zhao
Journal:  Oncol Lett       Date:  2019-11-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.